Literature DB >> 10896793

The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.

R Baluna1, E Coleman, C Jones, V Ghetie, E S Vitetta.   

Abstract

Immunotoxins (ITs) containing plant or bacterial toxins have a dose-limiting toxicity of vascular leak syndrome (VLS) in humans. The active A chain of ricin toxin (RTA), other toxins, ribosome-inactivating proteins, and the VLS-inducing cytokine IL-2 contain the conserved sequence motif (x)D(y) where x = L, I, G, or V and y = V, L, or S. RTA-derived LDV-containing peptides attached to a monoclonal antibody, RFB4, induce endothelial cell (EC) damage in vitro and vascular leak in two animal models in vivo. We have now investigated the mechanism(s) by which this occurs and have found that (1) the exposed D75 in the LDV sequence in RTA and the C-terminal flanking threonine play critical roles in the ability of RFB4-conjugated RTA peptide to bind to and damage ECs and (2) the LDV sequence in RTA induces early manifestations of apoptosis in HUVECs by activating caspase-3. These data suggest that RTA-mediated inhibition of protein synthesis (due to its active site) and apoptosis (due to LDV) may be mediated by different portions of the RTA molecule. These results suggest that ITs prepared with RTA mutants containing alterations in LDVT may kill tumor cells in vivo in the absence of EC-mediated VLS. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896793     DOI: 10.1006/excr.2000.4954

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  17 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

2.  Transition state analogues in structures of ricin and saporin ribosome-inactivating proteins.

Authors:  Meng-Chiao Ho; Matthew B Sturm; Steven C Almo; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-17       Impact factor: 11.205

3.  Immunotoxins: a promising treatment modality for metastatic melanoma?

Authors:  Karianne Risberg; Oystein Fodstad; Yvonne Andersson
Journal:  Ochsner J       Date:  2010

4.  Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.

Authors:  Weon-Kyoo You; Ian Kasman; Dana D Hu-Lowe; Donald M McDonald
Journal:  Am J Pathol       Date:  2010-02-25       Impact factor: 4.307

5.  Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.

Authors:  Xiao-yun Liu; Laurentiu M Pop; John Schindler; Ellen S Vitetta
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

6.  Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein.

Authors:  Matthew B Sturm; Peter C Tyler; Gary B Evans; Vern L Schramm
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

7.  Role of p38 MAP kinase pathway in a toxin-induced model of hemolytic uremic syndrome.

Authors:  Xue Jun Fu; Kazumoto Iijima; Kandai Nozu; Kiyoshi Hamahira; Ryojiro Tanaka; Tatsuya Oda; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2004-06-17       Impact factor: 3.714

Review 8.  Use of antibodies and immunoconjugates for the therapy of more accessible cancers.

Authors:  Robert M Sharkey; David M Goldenberg
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

9.  Circular DNA and DNA/RNA hybrid molecules as scaffolds for ricin inhibitor design.

Authors:  Matthew B Sturm; Setu Roday; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2007-04-07       Impact factor: 15.419

Review 10.  Ribosome-inactivating proteins: from plant defense to tumor attack.

Authors:  Maddalena de Virgilio; Alessio Lombardi; Rocco Caliandro; Maria Serena Fabbrini
Journal:  Toxins (Basel)       Date:  2010-11-10       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.